Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by PTBaileyon May 06, 2021 7:27am

172 Views

Post# 33138913

Investigational Use of Nitric Oxide Webinar

 						PLEASE TAKE NOTICE THAT THIS WEBINAR IS FROM OUR AUSTRALIA NTM GROUP, SO AUSSIE 
 						DATE/TIME IS MAY 7, 9:00AM(AUSTRALIA EASTERN STANDARD TIME) 

 						MAY 6 AT 7:00PM (EDT) - EASTERN DAYLIGHT TIME (NYC) FOR THE UNITED STATES. 
 						MAY 7, 9:00AM (AEST) - AUSTRALIA EASTERN STANDARD TIME FOR AUSTRALIA
 						
 						https://events.r20.constantcontact.com/register/m?oeidk=a07ehuysg6uc383ecba&oseq&c&ch